http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Study of Physical Treatment of Spent Military Use Lithium Primary Batteries for Recycling
Sohn, Jeong-Soo,Shin, Shun-Myung,Yang, Dong-Hyo,Kang, Jin-Gu,Yoo, Kyoung-Keun 한국암반공학회 2007 Geosystem engineering Vol.10 No.2
Physical treatment of lithium primary batteries without explosion is required to recycle the lithium primary batteries which could be exploded by heating too much or crushing. The safe dismantlement method of the spent lithium primary batteries has been required to recycle the batteries because the batteries contain lithium metal although the batteries are discharged. In the present study, safe dismantlement of the spent batteries was investigated, and then feasibility study was performed to recycle scraps of the spent batteries. As written above, the batteries were safely crushed, and metals such as nickel were recovered. Further study was required to increase recovery ratio and purity of metal.
Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study
Mi-Kyoung Kang,Yooha Hong,Yoo Hwan Kim,Hong-Kyun Park,Soo-Kyoung Kim,Jong-Hee Sohn,Jiyoung Kim,Ki-Han Kwon,Soo-Jin Cho 대한신경과학회 2024 Journal of Clinical Neurology Vol.20 No.3
Background and Purpose Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the current management status of patients with GCA using Korean multicenter data. Methods This retrospective study analyzed medical records of patients with GCA at six Korean university hospitals from February 2009 to November 2022. GCA had originally been diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, and cases were selected for inclusion in this study based on the 2022 ACR/European Alliance of Associations for Rheumatology criteria. We evaluated treatments, follow-up periods, and outcomes (relapse, remission, and adverse drug reactions) in patients with GCA with or without arteritic anterior ischemic optic neuropathy (AAION). Results This study analyzed 18 patients with a median age of 75.5 years that included 12 females (66.7%). Seven patients (38.8%) had AAION. All patients initially received prednisolone treatment, while four (22.2%) underwent adjuvant treatment with methotrexate and azathioprine during prednisolone tapering. During the median follow-up of 3.5 months (interquartile range: 2.0–23.2 months), 4 patients (22.2%) had prednisolone-related adverse reactions, 2 (11.1%) relapsed, and 13 (72.3%) dropped out. Nine patients (50.0%) experienced remission, with this being sustained in four (36.4%). Conclusions This study observed high dropout rates and short follow-ups. Adverse effects of prednisolone were common, and relapses occurred in approximately one-tenth of Korean patients with GCA. Thus, optimizing GCA treatment necessitates regular monitoring and longterm follow-up.
Hong Eun Kyoung,Choi Seung Hong,Shin Dong Jae,Jo Sang Won,Yoo Roh-Eul,Kang Koung Mi,Yun Tae Jin,김지훈,Sohn Chul-Ho,Park Sung-Hye,Won Jae-Kyoung,Kim Tae Min,Park Chul-Kee,Kim Il Han,Lee Soon-Tae 대한영상의학회 2021 Korean Journal of Radiology Vol.22 No.2
Objective: To evaluate the association of MRI features with the major genomic profiles and prognosis of World Health Organization grade III (G3) gliomas compared with those of glioblastomas (GBMs). Materials and Methods: We enrolled 76 G3 glioma and 155 GBM patients with pathologically confirmed disease who had pretreatment brain MRI and major genetic information of tumors. Qualitative and quantitative imaging features, including volumetrics and histogram parameters, such as normalized cerebral blood volume (nCBV), cerebral blood flow (nCBF), and apparent diffusion coefficient (nADC) were evaluated. The G3 gliomas were divided into three groups for the analysis: with this isocitrate dehydrogenase (IDH)-mutation, IDH mutation and a chromosome arm 1p/19q-codeleted (IDHmut1p/19qdel), IDH mutation, 1p/19q-nondeleted (IDHmut1p/19qnondel), and IDH wildtype (IDHwt). A prediction model for the genetic profiles of G3 gliomas was developed and validated on a separate cohort. Both the quantitative and qualitative imaging parameters and progression-free survival (PFS) of G3 gliomas were compared and survival analysis was performed. Moreover, the imaging parameters and PFS between IDHwt G3 gliomas and GBMs were compared. Results: IDHmut G3 gliomas showed a larger volume (p = 0.017), lower nCBF (p = 0.048), and higher nADC (p = 0.007) than IDHwt. Between the IDHmut tumors, IDHmut1p/19qdel G3 gliomas had higher nCBV (p = 0.024) and lower nADC (p = 0.002) than IDHmut1p/19qnondel G3 gliomas. Moreover, IDHmut1p/19qdel tumors had the best prognosis and IDHwt tumors had the worst prognosis among G3 gliomas (p < 0.001). PFS was significantly associated with the 95th percentile values of nCBV and nCBF in G3 gliomas. There was no significant difference in neither PFS nor imaging features between IDHwt G3 gliomas and IDHwt GBMs. Conclusion: We found significant differences in MRI features, including volumetrics, CBV, and ADC, in G3 gliomas, according to IDH mutation and 1p/19q codeletion status, which can be utilized for the prediction of genomic profiles and the prognosis of G3 glioma patients. The MRI signatures and prognosis of IDHwt G3 gliomas tend to follow those of IDHwt GBMs.
Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma
Hong, Eun Kyoung,Choi, Seung Hong,Shin, Dong Jae,Jo, Sang Won,Yoo, Roh-Eul,Kang, Koung Mi,Yun, Tae Jin,Kim, Ji-Hoon,Sohn, Chul-Ho,Park, Sung-Hye,Won, Jae-Kyung,Kim, Tae Min,Park, Chul-Kee,Kim, Il Han Springer-Verlag 2018 EUROPEAN RADIOLOGY Vol.28 No.10
Lee, Je-Hwan,Kim, Yoo-Jin,Sohn, Sang Kyun,Yoon, Sung-Soo,Kim, Hawk,Cheong, June-Won,Lee, Won-Sik,Lee, Gyeong-Won,Lim, Sung-Nam,Kim, Min Kyoung,Lee, Ho Sup,Kim, Hyeoung-Joon Elsevier 2017 Leukemia research Vol.60 No.-
<P><B>Abstract</B></P> <P>We retrospectively analyzed the results of hypomethylating therapy in 586 patients (azacitidine in 423 and decitabine in 163) with International Prognostic Scoring System (IPSS) lower-risk myelodysplastic syndrome (MDS). The patients were reclassified with newer scoring systems (revised IPSS [R-IPSS], revised WHO classification-based Prognostic Scoring System [R-WPSS], and Lower Risk Prognostic Scoring System [LR-PSS]), and 21.8–38.4% of patients had high or very high risk features by the newer scoring systems. Median overall survival (OS) was 27.3 months and newer scoring systems well stratified the patients in terms of OS (R-IPSS, <I>P</I> =0.001; R-WPSS, <I>P<</I> 0.001; LR-PSS, <I>P<I> <</I> </I> 0.001). Hematologic improvement (HI) was observed in 279 patients (47.6%). OS differed by the achievement of HI (39.4% vs. 36.2%, <I>P</I> =0.067). The differences were significant only in patients of intermediate or high risk group by LR-PSS (<I>P</I> =0.034) or R-IPSS (<I>P</I> =0.018). In summary, IPSS lower-risk MDS included a broad range of prognosis, and hypomethylating therapy induced HI in approximately half of the patients. Achievement of HI was associated with longer survival, especially in patients with intermediate or high risk features by newer scoring systems. Hypomethylating therapy seems to have potential benefits in IPSS lower-risk MDS.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Some IPSS lower-risk patients had high risk features by newer scoring systems. </LI> <LI> IPSS lower-risk patients were well stratified by newer systems for survivals. </LI> <LI> Hematologic improvement was observed in 48% after hypomethylating therapy. </LI> <LI> Achievement of hematologic improvement was associated with longer survival. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Ryou, Jeong-Hyun,Sohn, Yoo-Kyoung,Hwang, Da-Eun,Kim, Hak-Sung Elsevier 2015 Biochemical and biophysical research communication Vol.464 No.4
<P><B>Abstract</B></P> <P>The cell-specific cytosolic delivery of functional macromolecules with high efficiency is of great significance in molecular medicine and biotechnology. Herein, we present a Shiga-like toxin II-based high-efficiency and receptor-specific intracellular delivery system. We designed and constructed the Shiga-like toxin-based carrier (STC) to comprise the targeting and translocation domains, and used it for delivering a protein cargo. The STC was shown to deliver a protein cargo into the cytosol with high efficiency in a receptor-specific manner, exhibiting much higher efficiency than the most widely used cell-penetrating peptide. The general utility of the STC was demonstrated by modulating the targeting domain. The present delivery platform can be widely used for the intracellular delivery of diverse biomolecules in a receptor-specific and genetically encodable manner.</P> <P><B>Highlights</B></P> <P> <UL> <LI> We present a highly efficient and cell-specific intracellular delivery system. </LI> <LI> Shiga-like toxin-based carrier comprises the targeting and translocation domain. </LI> <LI> EGFP was successfully delivered into the cytoplasm of mammalian cells. </LI> <LI> The receptor-specificity was changed by modulating the targeting domain. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>